Prospective comparative study about influence on gut microbiome by medication of fexuprazan and esomeprazole

Not Applicable

Recruiting

• Conditions: Diseases of the digestive system

• Registration Number: KCT0008702
• Lead Sponsor: Ajou University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 August 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients diagnosed with reflux esophagitis by upper gastrointestinal endoscopy.
Age: 40 to 80 years old

Exclusion Criteria

? Helicobacter pylori positive patient
? Patients with drug allergies to fexuprazan or esomeprazole
? a patient with a history of gastrectomy or bowel resection
? Patients under 40 or over 80 years of age
? Patients with therapeutic history of antibiotics or gastric acid secretion inhibitors (proton pump inhibitors, histamine-2 receptor blockers, potassium competitive gastric acid secretion inhibitors) over the past 6 months
? Patients diagnosed with inflammatory bowel disease (cron disease, ulcerative colitis) or irritable bowel syndrome
? a patient on immunosuppressants
? Patients who are scheduled to receive oral or intravenous anticancer drugs
? a pregnant woman

Study & Design

• Study Type: Observational Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
microbial diversity between PPI and PCAB(4weeks and 12 weeks, respectively): alpha and beta divertsity

Secondary Outcome Measures

Name	Time	Method
functional analysis of changed gut microbiome using PICRUSt software, correlation between change of microbiome and dietary habit